{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:08:45Z","timestamp":1777298925425,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scott Canning Tour de Cure Wilson Centre for Lymphoma Genomics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1038\/s41375-023-01863-7","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T10:02:45Z","timestamp":1678528965000},"page":"1092-1102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study"],"prefix":"10.1038","volume":"37","author":[{"given":"Kate","family":"Manos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colm","family":"Keane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sze-Ting","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charmaine","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid","family":"Churilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"McKendrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Renwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piers","family":"Blombery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niles Elizabeth","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tineke","family":"Fancourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Hawking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1615-0540","authenticated-orcid":false,"given":"Allison","family":"Barraclough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-2392","authenticated-orcid":false,"given":"Joel","family":"Wight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun Yew","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-2559","authenticated-orcid":false,"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"1863_CR1","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116:2040\u20135.","journal-title":"Blood"},{"key":"1863_CR2","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":"Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303. J Clin Oncol. 2019;37:1790\u20139.","journal-title":"J Clin Oncol"},{"key":"1863_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1817\u201326.","journal-title":"Lancet"},{"key":"1863_CR4","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","volume":"35","author":"JP Leonard","year":"2017","unstructured":"Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, et al. Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2017;35:3538\u201346.","journal-title":"J Clin Oncol"},{"key":"1863_CR5","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:1285\u201395.","journal-title":"J Clin Oncol"},{"key":"1863_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2021","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N. Engl Med. 2021;386:351\u201363.","journal-title":"N. Engl Med"},{"key":"1863_CR7","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trneny M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35:3529\u201337.","journal-title":"J Clin Oncol"},{"key":"1863_CR8","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","volume":"126","author":"J Kiyasu","year":"2015","unstructured":"Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126:2193\u2013201.","journal-title":"Blood"},{"key":"1863_CR9","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1182\/blood-2018-10-879015","volume":"133","author":"J Godfrey","year":"2019","unstructured":"Godfrey J, Tumuluru S, Bao R, Leukam M, Venkataraman G, Phillip J, et al. PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T cell-inflamed phenotype. Blood. 2019;133:2279\u201390.","journal-title":"Blood"},{"key":"1863_CR10","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3324\/haematol.2019.243626","volume":"106","author":"A Matias","year":"2020","unstructured":"Matias A, Suvi-Katri L, Oscar B, Satu M, Judit M\u00e9sz\u00e1ros J, Marja-Liisa K-L, et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica. 2020;106:718\u201329.","journal-title":"Haematologica"},{"key":"1863_CR11","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","volume":"2","author":"C Keane","year":"2015","unstructured":"Keane C, Vari F, Hertzberg M, Cao KAL, Green MR, Han E, et al. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematol. 2015;2:e445\u201355.","journal-title":"Lancet Haematol"},{"key":"1863_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41379-018-0193-5","volume":"32","author":"L Li","year":"2019","unstructured":"Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, et al. PD-1\/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Mod Pathol. 2019;32:741\u201354.","journal-title":"Mod Pathol"},{"key":"1863_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1182\/blood-2018-99-110220","volume":"132","author":"P Armand","year":"2018","unstructured":"Armand P, Rodig SJ, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL): data from the Keynote-013 and Keynote-170 studies. Blood. 2018;132:228.","journal-title":"Blood"},{"key":"1863_CR14","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","volume":"129","author":"L Nayak","year":"2017","unstructured":"Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071\u20133.","journal-title":"Blood"},{"key":"1863_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.18.00766","volume":"37","author":"SM Ansell","year":"2019","unstructured":"Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, et al. Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37:481\u20139.","journal-title":"J Clin Oncol"},{"key":"1863_CR16","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl J Med. 2018;378:1976\u201386.","journal-title":"N. Engl J Med"},{"key":"1863_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566\u201376.","journal-title":"Nat Med"},{"key":"1863_CR18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/bjh.16494","volume":"189","author":"SD Smith","year":"2020","unstructured":"Smith SD, Till BG, Shadman MS, Lynch RC, Cowan AJ, Wu QV, et al. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. Br J Haematol. 2020;189:1119\u201326.","journal-title":"Br J Haematol"},{"key":"1863_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12185-021-03241-4","volume":"115","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Willenbacher W, Greil R, Larsen TS, Patel K, J\u00e4ger U, et al. Safety and efficacy of durvalumab with R-CHOP or R(2)-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. Int J Hematol. 2021;115:222\u201332.","journal-title":"Int J Hematol"},{"key":"1863_CR20","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1182\/blood-2019-123368","volume":"134","author":"A Younes","year":"2019","unstructured":"Younes A, Burke JM, Cheson BD, Diefenbach C, Ferrari S, Hahn UH, et al. Safety and efficacy of atezolizumab in combination with rituximab plus CHOP in previously untreated patients with diffuse large B-cell lymphoma (DLBCL): updated analysis of a phase I\/II study. Blood. 2019;134:2874\u201374.","journal-title":"Blood"},{"key":"1863_CR21","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","volume":"6","author":"PJ Br\u00f6ckelmann","year":"2020","unstructured":"Br\u00f6ckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, et al. Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol. 2020;6:872\u201380.","journal-title":"JAMA Oncol"},{"key":"1863_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/imm.12913","volume":"154","author":"E Hughes","year":"2018","unstructured":"Hughes E, Scurr M, Campbell E, Jones E, Godkin A, Gallimore A. T-cell modulation by cyclophosphamide for tumour therapy. Immunology. 2018;154:62\u20138.","journal-title":"Immunology"},{"key":"1863_CR23","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-18-1393","volume":"9","author":"C Lossos","year":"2019","unstructured":"Lossos C, Liu Y, Kolb KE, Christie AL, Van Scoyk A, Prakadan SM, et al. Mechanisms of lymphoma clearance induced by high-dose alkylating agents. Cancer Disco. 2019;9:944\u201361.","journal-title":"Cancer Disco"},{"key":"1863_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.neo.2015.08.004","volume":"17","author":"J Rios-Doria","year":"2015","unstructured":"Rios-Doria J, Durham N, Wetzel L, Rothstein R, Chesebrough J, Holoweckyj N, et al. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models. Neoplasia. 2015;17:661\u201370.","journal-title":"Neoplasia"},{"key":"1863_CR25","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359\u201368.","journal-title":"Oncogene"},{"key":"1863_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/hon.2803","volume":"38","author":"B Casadei","year":"2020","unstructured":"Casadei B, Argnani L, Morigi A, Lolli G, Broccoli A, Pellegrini C, et al. Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed\/refractory Hodgkin lymphoma: a real-life experience. Hematol Oncol. 2020;38:737\u201341.","journal-title":"Hematol Oncol"},{"key":"1863_CR27","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ajh.25154","volume":"93","author":"C Rossi","year":"2018","unstructured":"Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: a series from lysa centers. Am J Hematol. 2018;93:1042\u20139.","journal-title":"Am J Hematol"},{"key":"1863_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/bjh.16756","volume":"191","author":"NA Carreau","year":"2020","unstructured":"Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, et al. Checkpoint blockade treatment sensitises relapsed\/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020;191:44\u201351.","journal-title":"Br J Haematol"},{"key":"1863_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.18183","volume":"198","author":"E Calabretta","year":"2022","unstructured":"Calabretta E, Guidetti A, Ricci F, Di Trani M, Monfrini C, Magagnoli M, et al. Chemotherapy after PD-1 inhibitors in relapsed\/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics. Br J Haematol. 2022;198:82\u201392.","journal-title":"Br J Haematol"},{"key":"1863_CR30","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","volume":"3","author":"B Boyerinas","year":"2015","unstructured":"Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3:1148\u201357.","journal-title":"Cancer Immunol Res"},{"key":"1863_CR31","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds). WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. International Agency for Research on Cancer, Lyon, 2017."},{"key":"1863_CR32","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","volume":"123","author":"DW Scott","year":"2014","unstructured":"Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214\u20137.","journal-title":"Blood"},{"key":"1863_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.","journal-title":"Blood"},{"key":"1863_CR34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/ejh.13274","volume":"103","author":"C Keane","year":"2019","unstructured":"Keane C, Tobin J, Gunawardana J, Francis S, Gifford G, Gabrielli S, et al. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma. Eur J Haematol. 2019;103:200\u20137.","journal-title":"Eur J Haematol"},{"key":"1863_CR35","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1200\/jco.2015.33.15_suppl.3044","volume":"33","author":"K Kelly","year":"2015","unstructured":"Kelly K, Patel MR, Infante JR, Iannotti N, Nikolinakos P, Leach J, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study. J Clin Oncol. 2015;33:3044\u201344.","journal-title":"J Clin Oncol"},{"key":"1863_CR36","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"1863_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/ejh.13684","volume":"107","author":"J Wight","year":"2021","unstructured":"Wight J, Wai SH, Shen E, Lee S-T, Berlangieri S, Fancourt T, et al. Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma. Eur J Haematol. 2021;107:475\u201383.","journal-title":"Eur J Haematol"},{"key":"1863_CR38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/jclinpath-2018-205195","volume":"71","author":"GL Ryland","year":"2018","unstructured":"Ryland GL, Jones K, Chin M, Markham J, Aydogan E, Kankanige Y, et al. Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing. J Clin Pathol. 2018;71:895\u20139.","journal-title":"J Clin Pathol"},{"key":"1863_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-015-0088-7","volume":"3","author":"A Cesano","year":"2015","unstructured":"Cesano A. nCounter\u00ae PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA). J Immunother Cancer. 2015;3:42.","journal-title":"J Immunother Cancer"},{"key":"1863_CR40","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ccell.2020.06.002","volume":"38","author":"O Dufva","year":"2020","unstructured":"Dufva O, P\u00f6l\u00f6nen P, Br\u00fcck O, Ker\u00e4nen MAI, Klievink J, Mehtonen J, et al. Immunogenomic landscape of hematological malignancies. Cancer Cell. 2020;38:380\u2013.e313.","journal-title":"Cancer Cell"},{"key":"1863_CR41","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128:2489\u201396.","journal-title":"Blood"},{"key":"1863_CR42","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","volume":"36","author":"MJ Maurer","year":"2018","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Link BK, Jais J-P, Habermann TM, Thompson CA, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018;36:1603\u201310.","journal-title":"J Clin Oncol"},{"key":"1863_CR43","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927\u201332.","journal-title":"Blood"},{"key":"1863_CR44","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28:1436\u201347.","journal-title":"Ann Oncol"},{"key":"1863_CR45","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1182\/blood-2021-147042","volume":"138","author":"P Allen","year":"2021","unstructured":"Allen P, Chen QC, Lu X, O\u2019Shea K, Chmiel J, Sukhanova M, et al. Frontline treatment with single agent pembrolizumab (PEM) followed by AVD chemotherapy for classic Hodgkin lymphoma: updated results and correlative analysis. Blood. 2021;138:231\u201331.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01863-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01863-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01863-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T10:56:21Z","timestamp":1683716181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01863-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1863"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01863-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KM has received travel expenses from Bristol Myers Squibb. GC has acted as a consultant\/advisor for Bristol Myers Squibb Foundation (paid to institution) and received research funding from AstraZeneca, Bayer, Bristol-Myers Squibb, Hutchison MediPharma, Isofol Medical, Merck Serono, Pharmacyclics, Regeneron, SERVIER (all paid to institution). CK has received honoraria from Roche, Beigene, Karyopharm Therapeutics. WR has received research funding from GSK, Janssen, MorphoSys and Incyte (all paid to institution). AS has acted as a consultant for Imagion; received research funding from Telix, Curis, ITM, Adalta, Fusion, Astra Zeneca, EMD Serono, Cyclotek, AVID\/Lilly and Merck (all paid to institution); and holds patents relating to antibodies to EGFR, HER2, PDGF-CC, FN-14, GM-CSF and EPhA3. AB has acted as a speaker for Roche and as a consultant\/advisor for Gilead. JW has received honoraria and travel subsidies from Abbvie and Janssen; and is on the advisory board for Abbive and Alexion. CF has received honoraria from Abbvie, Amgen, Bristol-Myers Squibb, Novartis and Pfizer; has acted as a consultant\/advisor for Abbvie, Amgen, Astellas Pharma, Bristol-Myers Squibb, Novartis and Pfizer; and has received research funding from Amgen and Astellas Pharma. EAH has received research funding Bristol Myers Squibb\/Celgene, Merck KgA, Astra Zeneca, and F. Hoffmann-La Roche (all paid to institution); has acted as a consultant\/advisor for F. Hoffmann-La Roche, Antigene, Bristol Myers Squibb, Astra Zeneca, Novartis, Merck Sharpe Dohme, Specialised therapeutics and Gilead; has acted as a speaker for Roche, Astra Zeneca, Janssen, and Regeneron. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}